Recombinant Mouse TNFRSF18 Protein, Fc-tagged

• Cat.No.: TNFRSF18-663M
• Product Overview: Recombinant Mouse TNFRSF18 protein with Fc tag was expressed in HEK293.

Specification

• Description: Predicted to enable tumor necrosis factor-activated receptor activity. Involved in positive regulation of cell adhesion. Located in external side of plasma membrane. Is expressed in genitourinary system; gut; heart ventricle; lung; and skin. Orthologous to human TNFRSF18 (TNF receptor superfamily member 18).
• Source: HEK293
• Species: Mouse
• Tag: Fc
• Form: Lyophilized
• Molecular Mass: 40.3 kDa
• Protein length: 250
• AA Sequence: MGAWAMLYGVSMLCVLDLGQPSVVE EPGCGPGKVQNGSGNNTRCCSLYAP GKEDCPKERCICVTPEYHCGDPQCK ICKHYPCQPGQRVESQGDIVFGFRC VACAMGTFSAGRDGHCRLWTNCSQF GFLTMFPGNKTHNAVCIPEPLPTEQ YGHLTVIFLVMAACIFFLTTVQLGL HIWQLRRQHMCPRETQPFAEVQLSA EDACSFQFPEEERGEQTEEKCHLGG RWAMRPGLPLCPKPDATRLAQLYPW
• Purity: > 98%
• Applications: WB; ELISA; FACS; FC
• Stability: This bioreagent is stable at 4 centigrade (short-term) and -70 centigrade(long-term). After reconstitution, sample may be stored at 4 centigrade for 2-7 days and below -18 centigrade for future use.
• Storage: At -20 centigrade.
• Concentration: 1 mg/mL
• Storage Buffer: PBS (pH 7.4-7.5). Sterile-filtered colorless solution.
• Reconstitution: Reconstitute in sterile distilled H2O to no less than 100 μg/mL; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.

Gene Information

• Gene Name: Tnfrsf18 tumor necrosis factor receptor superfamily, member 18 [ Mus musculus (house mouse) ]
• Official Symbol: TNFRSF18
• Synonyms: TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18; glucocorticoid-induced TNFR-related protein; AITR; Gitr
• Gene ID: 21936
• mRNA Refseq: NM_009400
• Protein Refseq: NP_033426
• UniProt ID: O35714

Reviews

12/20/2021

This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

03/05/2020

Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

10/01/2017

The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

Q&As

What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment?

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment?

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies?

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes?

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies?

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.